OncoMed Presents GITRL-Fc Research at the AACR Annual Meeting 2016
19 avr. 2016 09h00 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., April 19, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), presented new data related to its GITRL-Fc immuno-oncology therapeutic candidate at the...
OncoMed Initiates Phase 1b Immuno-Oncology Combination Clinical Trial for Demcizumab and Pembrolizumab (anti-PD1)
17 mars 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
OncoMed to Present Data at the American Association of Cancer Research Annual Meeting 2016
16 mars 2016 16h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 16, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) will present new data related to its clinical and preclinical anti-cancer stem cell and...
OncoMed Pharmaceuticals Announces Full Year and Fourth Quarter 2015 Financial Results and 2016 Guidance
10 mars 2016 16h04 HE
|
OncoMed Pharmaceuticals, Inc.
Projects Two Years’ Cash Runway – without Partner-related Milestones/Opt-ins OncoMed Management to Host Conference Call/Webcast this Afternoon at 4:30 p.m. ET/1:30 p.m. PT REDWOOD CITY, Calif.,...
OncoMed Pharmaceuticals to Report Fourth Quarter and Year-End 2015 Financial Results on Thursday, March 10, 2016
04 mars 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., March 04, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage company developing novel cancer stem cell (CSC) and immuno-oncology...
OncoMed Presents Updated Phase 1b Data for Tarextumab in Small Cell Lung Cancer
22 févr. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
Higher Doses of Tarextumab Appear to Correlate with Improved Progression-free and Overall Survival REDWOOD CITY, Calif., Feb. 22, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc....
OncoMed Provides Update on Tarextumab Phase 2 Programs
08 févr. 2016 08h00 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Feb. 08, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
OncoMed Pharmaceuticals to Present at Upcoming Investor Conferences
04 févr. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Feb. 04, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
OncoMed Provides Update on Tarextumab Phase 2 Pancreatic Cancer ALPINE Trial
25 janv. 2016 07h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 25, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...
OncoMed Presents Updated Phase 1b Data for Demcizumab in First-Line Pancreatic Cancer at the Gastrointestinal Cancers Symposium
22 janv. 2016 08h30 HE
|
OncoMed Pharmaceuticals, Inc.
REDWOOD CITY, Calif., Jan. 22, 2016 (GLOBE NEWSWIRE) -- OncoMed Pharmaceuticals Inc. (NASDAQ:OMED), a clinical-stage company developing novel anti-cancer stem cell and immuno-oncology...